Skip to main content

Qiagen Added to Russell 1000 and Russell 3000 Indexes

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen today said that its common stock has been added to the US large-cap Russell 1000 Index and the broad market Russell 3000 Index.

Russell Investments reconstituted its equity indexes after the close of the market on Friday, resulting in Qiagen's inclusion, the molecular diagnostics and sample prep technologies firm said.

The Russell 3000 Index measures the performance of the 3,000 largest companies in the US and represents roughly 90 percent of the investible US equity market. The Russell 1000 Index represents the highest-ranking 1,000 companies in the US.

"This inclusion provides further support and liquidity for Qiagen's common shares, and thereby more benefits to participating in Qiagen's growth and creation of value for shareholders,” Qiagen CEO Peer Schatz said in a statement.

In early afternoon trading today on Nasdaq, shares of Qiagen were up 1 percent at $18.89.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.